As there are currently clinical trials using NLRP3 inhibitors for PD, it can be proposed that these molecules may be beneficial for COVID-19-related neurological symptoms, especially COVID-19-related neurodegeneration [6]. The gene discussed is NLRP3; the disease is COVID-19.